EUVIMEDEUVIMED entdecken
Crossref

Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies

Beibei Liang, Fei Li, Songhua Luan, Na Zhang, Jinru Zeng, Liping Dou, Yun Cai iD

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Beibei Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of Chinese PLA General Hospital, 28 Fu Xing Road, Haidian Distr…. Hauptthemen laut MEDLINE: Pyrazoles, Hematologic Neoplasms, Triazoles, Antifungal Agents. Die Arbeit nennt 19 Literaturangaben. Gefördert von: New Medicine Clinical Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study investigated CYP3A4-mediated pharmacokinetic interactions between ruxolitinib (JAK1/2 inhibitor for steroid-refractory acute and chronic graft-versus-host disease) and posaconazole (antifungal prophylaxis in haematological malignancies) to inform clinical dosing strategies.

Methods

In this open-label, fixed-sequence trial, eight Chinese patients with haematological malignancies received ruxolitinib 5 mg once daily (Day 1: monotherapy) followed by ruxolitinib 5 mg plus posaconazole 200 mg three times daily (Days 2–6: combination). Plasma concentrations of ruxolitinib and posaconazole were analysed using validated LC-MS/MS. Geometric mean ratios (GMRs) with 90% CIs for PK parameters were calculated to assess PK interactions.

Results

All patients completed the study. Co-administration with posaconazole increased ruxolitinib AUC0–24h by 58% (GMR: 1.58; 90% CI: 1.32–1.88). Geometric mean AUC0–24h values were 179.80 μg·h/L [monotherapy, coefficient of variation (CV) 39.26%] versus 283.60 μg·h/L (combination, CV 41.42%). No significant change in Cmax was observed (GMR: 1.10; 90% CI: 0.90–1.36). Geometric mean of the maximum plasma concentration at steady state (Cmax,ss) and AUC0–24h of posaconazole were 1543.52 μg/L (CV 41.81%) and 31 404.37 μg·h/L (CV 32.14%). There was no significant correlation between the systemic exposure of posaconazole (AUC or Cmax,ss) and the ratio of ruxolitinib AUC0–24h when co-administered versus administered alone.

Conclusions

Although co-administration of posaconazole with ruxolitinib resulted in a statistically significant increase in ruxolitinib systemic exposure, the magnitude of this interaction was clinically moderate. Although ruxolitinib dose adjustment may not be routinely required when used concomitantly with posaconazole, close monitoring for ruxolitinib-related adverse effects is recommended under this combination therapy setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesHematologic NeoplasmsTriazolesAntifungal AgentsCytochrome P-450 CYP3AHumansPyrimidinesNitrilesMaleDrug InteractionsMiddle AgedFemaleAdultAgedChinaYoung AdultTandem Mass Spectrometry

Substanzen

ruxolitinibPyrazolesPyrimidinesNitrilesposaconazoleTriazolesAntifungal AgentsCytochrome P-450 CYP3ACYP3A4 protein, human

Autor:innen und Institutionen

  • Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of Chinese PLA General Hospital, 28 Fu Xing Road, Haidian District, Beijing 100853, China.
  • Department of Hematology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100853, China.

ORCID-Profile: Yun Cai

Förderung

  • New Medicine Clinical Research Fund

Zitieren

APA

Liang, B., Li, F., Luan, S., Zhang, N., Zeng, J., Dou, L., & Cai, Y. (2026). Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf398

Vancouver

Liang B, Li F, Luan S, Zhang N, Zeng J, Dou L, et al. Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf398

BibTeX
@article{Liang2026,
  author = {Liang, Beibei and Li, Fei and Luan, Songhua and Zhang, Na and Zeng, Jinru and Dou, Liping and Cai, Yun},
  title = {Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf398}
}
Kostenlos starten →